We choose products where there is clear differentiation and an unmet clinical need.
As an independent, privately-held and profitable business, we can make decisions quickly. We have the resources and capabilities to explore innovative solutions to meet the needs of patients, prescribers, payers and partners alike.We offer a focused and committed approach and our abilities have been demonstrated through multiple product launches with various partners, in differing regulatory environments.Thanks to a strong balance sheet and a commercial focus, our business is able to invest in long-term collaborations and partnerships to expand our portfolio of products and to support our partners’ needs.
Our team has extensive experience working across a broad range of therapeutic areas.
Our current portfolio includes a wide range of products in three main therapeutic areas: women’s health, urology and endocrinology.
Our range of contraceptives has been designed to meet the differing needs of patients. With our patient-centric approach we were able to identify and implement an innovative approach in the complex contraceptive market.
We offer the broadest portfolio of oral contraceptives (OCs) in the UK and Ireland, and lead the market in this area. In fact, more than 1 in 31 women in the UK who use OC will be taking a Consilient Health pill.
Based upon this success in initial launch markets we are now in a position to take this experience and launch into new territories.
We are actively looking to expand our portfolio of medicines in women’s health and are exploring many new areas including medicines for the menopause, overactive bladder and other gynaecological conditions.
Find out more information about our products for women’s health.
1 MAT December 2018 IMS data
To discuss partnering opportunities in women's healthContact us
Bladder Pain Syndrome (BPS) or Interstitial Cystitis
Bladder pain syndrome (BPS) is also known as interstitial cystitis. BPS is an uncommon but debilitating condition, most commonly presenting in women, generally in their 40’s.
In Europe, treatment options have been limited to unlicensed medicines that are non-specific e.g. analgesia and tricyclic antidepressants. There are also medical devices such as bladder instillations that can be painful for the patient and require hospital admission and its associated costs.
Consilient Health are proud to offer patients a treatment option for this painful condition.
To discuss partnering opportunities in urologyContact us
Our Bone Health portfolio includes a growing number of vitamin D3 (colecalciferol) prescription medicines.
We recognised that the bone health market has unmet needs with a lack of dose and formulation choices for healthcare professionals and their patients.
We are proud to offer a broad range of doses and formulations which gives patients and healthcare professionals a choice of options to suit their needs and preferences.
Find out more information about our range of products for bone health.
Globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. 2
We have a slow release treatment for type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.
Find out more information about our products to treat diabetes.
Obesity has more than doubled in incidence globally since 1980. 1
One of our new therapies helps patients with obesity lose weight. Its mode of action offers an alternative to existing therapies currently on the market.
Find out more information about our obesity medicines.
1 World Health Organization 2016
2 Global report on diabetes, World Health Organisation, 7 April 2016.
To discuss partnering opportunities in endocrinologyContact us
We work with a broad range of pharmaceutical companies to develop and licence generic products for the UK market.
Find out more information about our generics offering in the UK.
To discuss partnering opportunities in genericsContact us